An overview of CAR T-cell clinical trial activity to 2021-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An overview of CAR T-cell clinical trial activity to 2021

Published:2021-01-01 Issue:1 Volume:1 Page:
ISSN:2732-4303
Container-title:Immunotherapy Advances
language:en
Short-container-title:

Author:

Adami Antonella¹,Maher John¹²³⁴^ORCID

Affiliation:

1. King’s College London, School of Cancer and Pharmaceutical Sciences, CAR Mechanics Lab, Guy’s Cancer Centre, London, UK

2. Department of Clinical Immunology and Allergy, King’s College Hospital NHS Foundation Trust, London, UK

3. Department of Immunology, Eastbourne Hospital, Kings Drive, East Sussex, UK

4. Leucid Bio Ltd., Guy’s Hospital, London, UK

Abstract

Summary Immunotherapy of cancer using chimeric antigen receptor-engineered T-cells has transformed the management of selected haematological malignancies, triggering intense clinical trial activity in this arena. This article summarises trial activity that has been published to date across the spectrum of haematological and solid tumour types.

Funder

Leucid Bio

Breast Cancer Now

British Lung Foundation

Wellcome Trust

Jon Moulton Charity Trust

Medical Research Council

Experimental Cancer Medicine Centre at King’s College London

King's Health Partners

King’s College London Cancer Research UK Cancer Centre

National Institute for Health Research

Guy’s and St Thomas’ NHS Foundation Trust

King's College London

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

http://academic.oup.com/immunotherapyadv/advance-article-pdf/doi/10.1093/immadv/ltab004/36533438/ltab004.pdf

Reference9 articles.

1. Cancer cell therapies: the clinical trial landscape;Yu;Nat Rev Drug Discov,2020

2. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions;Kuwana;Biochem Biophys Res Commun,1987(3)

3. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors;Eshhar;Proc Natl Acad Sci USA,1993(3)

4. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product;Finney;J Immunol,1998

5. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19;Kochenderfer;Blood,2010

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma;Cancer Immunology, Immunotherapy;2024-04-15

2. Access to CAR T-cell therapy: Focus on diversity, equity and inclusion;Blood Reviews;2024-01

3. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn;Nature Reviews Clinical Oncology;2023-10-30

4. A systems and computational biology perspective on advancing CAR therapy;Seminars in Cancer Biology;2023-09

5. Activation-inducible CAR expression enables precise control over engineered CAR T cell function;Communications Biology;2023-06-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3